Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion

Gynecologic Cancer

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Oncol.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators

doi: 10.1016/

Breast Cancer

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

N Engl J Med.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P

doi: 10.1056/NEJMoa1706450.

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Gastrointestinal Cancer

A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer

J Surg Oncol.

Sho S, Court CM, Winograd P, Russell MM, Tomlinson JS

doi: 10.1002/jso.24781.

COMMENTED

Gynecologic Cancer

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Cancer Biol Ther.

Frisone D, Charrier M, Clement S, Christinat Y, Thouvenin L, Homicsko K, Michielin O, Bodmer A, Chappuis PO, McKee TA, Tsantoulis P

doi: 10.1080/15384047.2019.1685291.

Genitourinary Cancer

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Eur Urol.

Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW

doi: 10.1016/j.eururo.2017.02.023.

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Breast Cancer

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers

Eur J Cancer.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)

doi: 10.1016/j.ejca.2017.07.004.

Gynecologic Cancer

Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report

J Obstet Gynaecol Res.

Tarumi Y, Mori T, Matsushima H, Kokabu T, Tsuchiya H, Kitawaki J

doi: 10.1111/jog.13496.

Related content

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer

Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers

Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report